Publikationen in Zusammenarbeit mit Forschern von AstraZeneca (United Kingdom) (1)

2022

  1. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268